Overview

A Study to Assess the Clinical Utility of Antipsychotic Medication Levels in Plasma as Determined by Liquid Chromatography-Tandem Mass Spectrometry

Status:
Terminated

Trial end date:
2016-01-01

Target enrollment:

Participant gender:

Summary

The purpose of this study is to determine the number of Medication Treatment Modifications (MTMs) made by the clinician at every visit when antipsychotic medication plasma levels (AMPL) results are available compared to when AMPL results are not available.

Phase:

Phase 2

Details

Lead Sponsor:

Janssen Research & Development, LLC

Treatments:

Antipsychotic Agents
Aripiprazole
Olanzapine
Paliperidone Palmitate
Quetiapine Fumarate
Risperidone